Charles River Laboratories International, Inc. has new and continuing collaborations with three drug discovery partners funded by the Wellcome Trust. Antabio, an anti-bacterial drug discovery company, Pcovery, a spin-out company focused on anti-fungals, and the British Columbia Cancer Agency, have all extended existing or entered new agreements with Charles River’s Global Discovery Services business.
 
As part of the agreements, Charles River will provide a comprehensive suite of in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), and medicinal chemistry services.
 
“We are delighted Antabio, Pcovery, and the British Columbia Cancer Agency selected Charles River as their partner for the Wellcome Trust’s Seeding Drug Discovery (SDD) funded programs,” said Emily Hickey, corporate senior vice president, Global Discovery Services, Charles River. “We look forward to supporting these organizations in their goal to identify new therapies to treat—and hopefully cure — diseases.”